The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


TRIUMEQ



ViiV Healthcare BVEU/1/14/940/001-002

Main Information

Trade NameTRIUMEQ
Active SubstancesDolutegravir
Abacavir
Lamivudine
Dosage FormFilm-coated tablet
Licence HolderViiV Healthcare BV
Licence NumberEU/1/14/940/001-002

Group Information

ATC CodeJ05AR Antivirals for treatment of HIV infections, combinations
J05AR13 Antivirals for treatment of HIV infections, combinations

Status

License statusAuthorised
Licence Issued01/09/2014
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back